NEW PATENT WO020028A1: SUBSTANTIALLY NON-TOXIC BIOLOGICALLY ACTIVE MUCOSAL ADJUVANTS IN VERTEBRATE SUBJECTS
Connect the dots...
"DUKE PATENTS" means patent application serial number 09/168910 entitled "Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects" filed October 8, 1998 in the United States Patent and Trademark Office, including all amendments, continuation applications, divisional applications, continuation-in-part applications, and reissues based thereon, and foreign counter parts thereto. 10Q on 2/14/2000
I was wondering why I could not find a patent with Herman Staats' name as the inventor and now I know why. The patent had not been issued until 4/13/2000.
Priority Number(s): Oct. 8, 1998 US1998000168910
Also:
"JOINT PATENTS" shall mean any patent or patent application that, first, has inventors from both CISTRON and DUKE, and, second, relates to the FIELD, and, third, has claims protecting the use of a mutant form of IL-1b as an intranasal vaccine adjuvant, and, fourth, is based on an invention disclosed to DUKE in an Invention Disclosure Form which was assigned File # 1689 and which is incorporated in its entirety as Exhibit A of this AGREEMENT. 2/14/2000 SEC FILING
Message 12905117
Bulletin of the World Health Organization
The International Journal of Public Health
Could a nasal spray protect people against human immunodeficiency virus?
...The adjuvant used so far in experimental mucosal vaccines in animals has been cholera toxin, but researchers doubt that this will be acceptable for human vaccines because it can sometimes trigger undesirable side effects. Also, says Herman Staats, a member of the Duke team, cholera toxin may not work as an adjuvant in countries where cholera is endemic.
...Mouse studies have shown that interleukin-1 is effective as an adjuvant for other immunogens, and that vaccines given via the nose can stimulate immune responses in the mucous membranes of the reproductive tract.
...An experimental vaccine developed by Haynes and his colleagues [Herman Staats] has already been tested in injected form in people and stimulates antibodies and T cells against the virus.
who.int
Message 13223838
...Our results indicate that IL-1Alpha and IL-1Beta may be useful as mucosal vaccine adjuvants. Such an adjuvant may be useful, and possibly required, for vaccine-mediated protection against pathogens that infect via the mucosal surfaces of the host such as HIV
Message 13222008
...CISTRON's recent patent...RESULTS: Animals receiving the liposome encapsulated IL-1b mixed with influenza A/Beijing H3N3 vaccine showed a significant increase in anti-influenza A antibody titer over those animals receiving vaccine alone or non-encapsulated vaccine/IL-1b.
Message 12753536 [This same method could be used for the HIV virus]
<<We could just be about eight months away from a new patent. >> I was wrong...just five weeks from the date that I posted that statement this important patent was issued.
Message 13025850
WO020028A1:
SUBSTANTIALLY NON-TOXIC BIOLOGICALLY ACTIVE MUCOSAL ADJUVANTS IN VERTEBRATE SUBJECTS
Inventor(s):
STAATS, HERMAN, F. HAYNES, BARTON, F. PATEL, DHAVALKUMAR, D. SEMPOWSKI, GREGORY, D.
Applicant(s):
DUKE UNIVERSITY, United States of America
Issued/Filed Dates:
April 13, 2000 / Oct. 6, 1999
Abstract:
A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1 alpha (IL-1 alpha ) and interleukin-1 beta (IL-1 beta ).
patents.ibm.com
...What CIST is willing to pay Duke University:
- $20,719.16 shall be paid to DUKE no later that September 15, 1999.
- $20,719.16 shall be paid to DUKE on completion of the Research and receipt by CISTRON of a final report .
- $100,000 upon the execution of this AGREEMENT
- $50,000 upon the issuance of the first patent in the United States of America based on DUKE PATENTS
- $25,000 upon the issuance of the first patent in the United States of America based on JOINT PATENTS
- $100,000 upon a decision by PMC to exercise its option to participate with CISTRON in the development of LICENSED PRODUCTS that are therapeutic vaccines.
- $100,000 upon a decision by PMC to exercise its option to participate with CISTRON in the development of LICENSED PRODUCTS that are prophylactic vaccines.
- $200,000 upon approval of the first New Drug Application with the FDA or Biologics License Application with the FDA for a LICENSED PRODUCT.
- $50,000 or ten percent (10%) [the greater of ] of the aggregate of any sublicensing fees or cash payments received by CISTRON
- $25,000 per year in every year that the development of LICENSED PRODUCTS is delayed [for an exclusive license]
- .5% Royalty on Net Sales
- 12.5% of any damages received in excess of legal expenses incurred by CISTRON in enforcing rights in the LICENSED PATENTS. Message 12905667 |
